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Abstract Among the pathogenic mechanisms underlying
central nervous system (CNS) diseases, oxidative stress is
almost invariably described. For this reason, numerous
attempts have been made to decrease reactive oxygen
species (ROS) with the administration of antioxidants as
potential therapies for CNS disorders. However, such
treatments have always failed in clinical trials. Targeting
specific sources of reactive oxygen species in the CNS (e.g.
NOX enzymes) represents an alternative promising option.
Indeed, NOX enzymes are major generators of ROS, which
regulate progression of CNS disorders as diverse as
amyotrophic lateral sclerosis, schizophrenia, Alzheimer
disease, Parkinson disease, and stroke. On the other hand,
in autoimmune demyelinating diseases, ROS generated by
NOX enzymes are protective, presumably by dampening
the specific immune response. In this review, we discuss
the possibility of developing therapeutics targeting
NADPH oxidase (NOX) enzymes for the treatment of
different CNS pathologies. Specific compounds able to
modulate the activation of NOX enzymes, and the conse-
quent production of ROS, could fill the need for disease-
modifying drugs for many incurable CNS pathologies.
Keywords NOX NADPH oxidase  Oxidative stress 
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Introduction: NOX NADPH oxidases
and their emerging role in CNS diseases
Central nervous system (CNS) diseases are heterogeneous
and have numerous etiologies. However, CNS patholo-
gies as diverse as progressive neurodegenerative disea-
ses, neuropsychopathological disorders, and stroke share
many pathogenic mechanisms, such as inflammation,
microglia activation, impaired neurotransmission, gluta-
mate-mediated excitotoxicity, mitochondrial dysfunction,
apoptosis, and increase of oxidative stress [78, 120].
Among these features of CNS diseases, NOX enzymes
are emerging as an important source of oxidants in the
CNS and key regulators of neurological pathologies
[112, 136, 142].
The NOX family consists of seven members (NOX1,
NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2),
each with a specific tissue distribution. The isoforms present
in the CNS are mostly NOX1, NOX2, and NOX4. Despite
their similar core structures, NOX isoforms have different
mechanisms of activation. NOX1, NOX2, and NOX3
require association with cytosolic components [p47phox,
p67phox, NOXO1 (NOX organizer type 1), NOXA1 (NOX
activator type 1)], NOX4 is constitutively active, and NOX5
and DUOXes are activated by intracellular Ca2? elevation
and direct phosphorylation [8, 42, 84].
NOX enzymes function to transfer electrons across
membranes, which then react with oxygen generating the
superoxide anion O2
-. Superoxide dismutates very rapidly
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to generate hydrogen peroxide and other reactive oxygen
species (ROS).
In physiological conditions, ROS generated by NOX
enzymes work as defense mechanisms against pathogens
and signaling molecules. NOX enzymes are increasingly
recognized as key regulators of pathological situations
where oxidative stress is involved and leads to tissue oxi-
dative damage, such as pulmonary fibrosis, diabetic
nephropathy, and vascular and CNS pathologies [81]. The
NOX2 isoform (previously known as gp91phox or the
phagocyte oxidase) is responsible for the respiratory oxi-
dative burst in neutrophils. However, NOX2 is also
expressed in the CNS, where it controls key neuronal func-
tions and neuroinflammatory processes. NOX2 is strongly
upregulated in different CNS disorders where it generates
large amounts of ROS. NOX2 activation is thought to reg-
ulate microglia activation, a hallmark of inflammatory
gliosis observed in neuroinflammatory degenerative disor-
ders [17, 85]. As a major source of ROS, NOX2 can induce
direct neuronal damage [128] and maintain microglial cells
in an activated stage where they produce neurotoxic mole-
cules like peroxynitrite and other inflammatory molecules
[94]. A protective role of NOX2 deficiency has been dem-
onstrated in animal models of Parkinson disease (PD),
Alzheimer disease (AD), amyotrophic lateral sclerosis
(ALS), and stroke (reviewed in [142]). The fact that
decreased NOX2-generated ROS is protective in diverse
CNS diseases implies that it must regulate a key aspect of the
pathological CNS. NOX2 in the microglia is not the only
target to be pursued. In fact, NOX2 inhibition also prevents
development of psychotic disorders without the microglia-
mediated neuroinflammatory components by controlling
key neuronal aspects such as neurotransmitter release and
GABAergic interneurons function [13]. Although NOX2
deletion leads to decreased signs of oxidative stress, the
exact role of NOX enzymes in CNS physiology and
pathology is still very incomplete. Recent studies have
involved NOX2 in the pathways related to NMDA receptor
activation, opening new perspectives of research [20, 143].
Another striking aspect of the complexity of the role of
NOX2 is the fact that NOX2 plays an anti-inflammatory
role in autoimmune-mediated diseases including autoim-
mune neuroinflammation. Indeed, an insufficient ROS
production by systemic antigen presenting cells, such as
mononuclear phagocytes, will favor autoimmune neuroin-
flammation. Genetic studies identified a polymorphism in
the Ncf1 gene coding for p47phox, a regulatory cytosolic
factor of NOX-dependent oxidant production, which is
associated with susceptibility in rheumatoid arthritis mod-
els and other autoimmune disorders [116], including
experimental allergic encephalomyelitis, an animal model
of multiple sclerosis (MS) [62], and experimental allergic
neuritis, a model of Guillain Barre´ syndrome [58]. The link
between Ncf1 and disease susceptibility was further con-
firmed in humans because circulating leukocytes of
patients affected by MS [110] and other autoimmune
neuropathies [109] have a lower capacity for ROS gener-
ation. These unexpected findings appear to be due to down-
regulation of T cells by NOX2-dependent ROS generation
in response to autoantigen presentation [63].
To summarize, there are two possible therapeutic
options using NOX enzymes as pharmacological targets
(Fig. 1): (1) in CNS diseases like stroke, PD, AD, ALS,
with a strong glutamate excitotoxicity component, the
inhibition of NOX enzymes is expected to be beneficial,
while (2) when the neuroinflammatory process is mediated
by peripheral immune cells, activation of NOX2 in antigen
presenting cells of the immune system is predicted to bring
a therapeutic effect.
Although it has been known for a long time that mito-
chondria are an important source of ROS in CNS disease
[113, 2], the role of NOX enzymes in CNS pathologies is
rapidly emerging. However, because of the presence of at
least three NOX isoforms in the CNS and the absence of
studies using specific NOX inhibitors, we focus here on
disease models where proof-of-principle studies using
knock-out or mutant mice are available. We discuss current
therapies and the potential for NOX-based therapeutics
either decreasing NOX activity or, on the contrary,
enhancing low NOX activity in CNS autoimmune disor-
ders. Finally, we discuss past and emerging small
molecules targeting NOX enzymes and their possible
advantages and risks in CNS-based pathologies.
Beneficial effect of NOX inhibition: potential CNS
indications
Amyotrophic lateral sclerosis (ALS)
ALS is a neurodegenerative disease of the motoneurons
that leads to complete paralysis and death. Its prevalence is
around 2 per 100,000. Several therapeutic approaches have
been proposed for the treatment of this disease with vary-
ing efficacy. Today, there are no treatments that can arrest,
or even substantially delay, the progression of ALS. The
only drug approved to treat ALS patients is RiluzoleTM,
which is thought to inhibit the presynaptic release of
glutamate. However, its therapeutic benefit is modest as in
randomized controlled trials, it prolonged survival by
approximately 4 months [15, 79], a statistical benefit which
is subjectively not perceived by patients, family members,
or physicians [50]. ALS has a strong inflammatory com-
ponent with, for instance, increased expression of COX-2,
but the benefit of COX-2 inhibitors, such as rofecoxib
and celecoxib for the treatment of ALS, remains uncertain.
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A protective effect of numerous compounds has been
described in animal models of ALS (anti-inflammatory
drugs, anti-glutamate agents, neurotrophic factors, antiox-
idant, anti-apoptotic, gene inductors, autophagy inducers),
but none of them significantly prolonged survival or
improved quality of life when translated to ALS patients.
Signs of oxidative stress are observed in ALS rodent
models and in ALS patients, such as 8-oxodeoxyguanosine
(8-oxodG), urinary 15-F(2t)-isoprostane, protein carbon-
ylation, and markers of lipid peroxidation [5, 7, 104, 106].
The most studied form of ALS is a familial ALS (FALS)
in which the antioxidant enzyme SOD1 is mutated
(SOD1G93A). However, surprisingly, the increase of oxi-
dative stress is not due to the lack of function of SOD1, but
rather to aggregation of mutant protein [124], leading to a
toxic gain of function of the mutated SOD1 protein, which
in turn has been proposed to activate NOX enzymes [54].
NOX2 and subunits are strongly upregulated in both ALS
mice and patients colocalizing with microglial markers
[164]. Arguments in favor of a beneficial effect of NOX
inhibition comes from experiments where transgenic mice
expressing human SOD1G93A were bred with mice defi-
cient for NOX1 or NOX2, which showed lifespan increases
of 33 and 97 days, respectively [97]. Another study using a
similar approach has shown that NOX2-deficiency in
SOD1G93A overexpressing mice decreased the production
of microglial-derived ROS, delayed neurodegeneration and
prolonged survival, although more modestly than the other
study (13 days) [164]. Because of absence of treatment and
the inexorable development of ALS, there is a real need for
testing new targets for the pharmacological approach of
ALS. In spite of important differences in the protective
potential of NOX inhibition in ALS mice, these pre-
liminary proof-of-principle experiments converge at
identifying NOX enzymes as primary target for a potential
treatment of ALS.
Alzheimer disease (AD)
Alzheimer disease (AD) represents the most common sin-
gle cause of age-associated dementia worldwide. Although
AD etiology is unclear, neurodegeneration in AD patient
brain is characterized by protein misfolding and accumu-
lation of Ab (derived from amyloid precursor protein APP)
and tau (a microtubule-associated protein) in plaques and
intraneuronal neurofibrillary tangles, respectively. Forma-
tion of these abnormal protein aggregates leads to severe
neuronal death and synaptic loss, associated with microg-
lial and astrocytic activation. Excessive production of
inflammatory mediators and ROS by activated glial cells
and damaged neurons contribute to reduced neuronal sur-
vival and disease progression.
Due to the decreased levels of neurotransmitters, and
especially of acetylcholine, in AD patient brain, the main
therapy currently used for AD consists in the administra-
tion of acetylcholinesterase inhibitors, such as tacrine,
donepezil, rivastigmine, and galantamine [103]. Another
drug also commonly used for AD treatment is memantine
Fig. 1 Schematic overview of
possible therapeutic indications
for NOX targeting compounds.
a In diseases characterized by
neurodegeneration and
neuroinflammation such as
Alzheimer, Parkinson,
Amyotrophic lateral sclerosis,
and stroke, excessive NOX2
activation in injured neurons
and activated microglia cells
leads to production of ROS and
oxidative damage. b In
neurological autoimmune
diseases, such as multiple
sclerosis and Guillain Barre´
syndrome, NOX2 activation
inhibits the excessive T cell
response and contributes to
remyelination and neuronal
survival
Pharmacological targeting of NOX in the CNS 2389
123
[103], which acts as a non-competitive antagonist of the
NMDA receptor, thereby reducing excitotoxicity due to the
excessive glutamate release associated with neurodegen-
eration [132]. Although these treatments can reduce AD
symptoms and improve cognitive functions, they do not
contribute to the resolution of disease or arrest its pro-
gression [103]. Current approaches to develop better
therapies include inhibition of Ab aggregation and/or
production, as well as inhibition of Ab/tau-dependent
neurotoxic effects [24]. Indeed, preventing the protein
misfolding or its direct consequences would represent a
more efficacious way to reduce or even reverse the pro-
gression of the disease.
The involvement of NOX activation in the pathological
mechanisms of AD has been described in several studies
based on in vitro experiments with cultures of microglia,
astrocytes, and neurons (reviewed in [142]). Moreover,
disease progression was prevented in a mouse model of AD
(overexpressing the Swedish mutation of APP, leading to
Ab fragment accumulations) after breeding with NOX2-
deficient mice. Deletion of NOX2 gene reduced the patho-
logic effects of Ab amyloid fragments, rather than the
spontaneous accumulation of plaques in the mouse brain
[119]. There is also evidence that NOX enzymes are
expressed and activated in AD patients as compared to
healthy controls: translocation of NOX2-associated sub-
units (p47phox, p67phox) to the membrane [140], as well
as increased NOX2 activation in the frontal and temporal
cortex of AD patients with mild cognitive impairment [3].
Interestingly, in this recent study, only the expression of
NOX2 regulatory cytosolic subunits (p47phox, p67phox,
and p40phox) were increased in AD patients, while the
expression of membrane-associated proteins (p22phox and
NOX2) remained stable [3]. In addition, increased levels of
NOX1 and NOX3 mRNA were found in early stage AD
patients [33], suggesting that other isoforms might contrib-
ute to this pathology. Nevertheless, in spite of increasingly
recognised importance of NOX in AD, free radicals of spe-
cific mitochondrial origin and uncoupling of endothelial
nitric oxide synthase are likely to be important mediators of
the general oxidant status observed in AD [102].
Parkinson disease (PD)
Among neurodegenerative diseases, Parkinson disease is
the disorder for which the best options for symptomatic
treatment exist, at least for the initial phases. Neurode-
generation occurs in the substantia nigra, leading to loss
of dopaminergic neurons, which is associated with motor
dysfunctions. Typical Parkinson-related symptoms include
shaking, rigidity, or slowness, and they can be diag-
nosed early in the course of the disease [135]. Treatment
consists of the administration of levodopa, a precursor of
dopamine, to compensate for the dopamine reduction.
Although levodopa alleviates early movement dysfunc-
tions, it does not provide a real cure to prevent the
progressive degeneration of dopaminergic neurons. Simi-
larly, other available treatments include dopamine receptor
agonists, or monoamine oxidase (MAO-B) and catechol-
O-methyl transferase (COMT) inhibitors, which reduce the
dopamine metabolism and increase its availability. These
drugs are often used alone at the first appearance of
symptoms, while, at later stage, they are used in combi-
nation with levodopa, which remains more efficacious, but
is associated with more undesirable side effects, such as
dyskinesia (Table 1). Both genetic and environmental
factors have been implicated in the etiology of Parkinson
[135]. However, misfolding and deposition of toxic
a-synuclein aggregates seem to be an initiating pathogenic
event of the disease, whereas the progressive degeneration
is due to glial activation [53]. Oxidative damage is thought
to contribute to these mechanisms, and mitochondrial
dysfunction has been proposed to be a major source of
ROS [55]. Yet, there is experimental evidence supporting
a role for NOX enzymes. Most of the data derive from
in vitro studies, indicating a major involvement of
NOX2 in microglia-dependent dopaminergic neurotoxicity
(reviewed in [142]). In addition, a direct expression of
NOX enzymes in dopaminergic neurons might play a role,
while microglia serve to amplify the neurotoxic stimuli
[17]. In line with these findings, decreased death of
dopaminergic neurons in NOX2-deficient mice as com-
pared to wild-type (WT) was detected following LPS-
injections in the substantia nigra [129] and systemic
administration of MPTP [170] or the herbicide paraquat
[127]. A recent study identified a possible mechanism by
which NOX2 could be involved in paraquat toxicity. In its
native form, paraquat is a divalent cation and is not a
substrate of dopaminergic transporters. It therefore
requires reduction into a monovalent cation by microglial
NOX2 in order to be a substrate for dopamine transporters
leading to its accumulation in dopaminergic neurons
[130]. Whether oxidative modification of a-synuclein or
other Parkinson causative agents increase their toxicity to
dopamine neurons remains unknown. Two recent studies
show evidence of a role of neuronal NOX1 in Parkinson
disease [28, 31]. At this stage, the role of different NOX
isoforms is not clear, but one could speculate that a cross-
talk exists between neuronal NOX (probably NOX1) and
microglial NOX2, which would act by amplifying the
neuronal damage and regulating a neuroinflammatory
response. In order to evaluate the exact effect of different
isoforms, backcross of NOX-deficient animals with
genetic models of PD should be performed [35].
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Schizophrenia
Schizophrenia is a severe psychiatric disorder character-
ized by three main symptoms: positive, such as
hallucinations and delusions, negative, such as loss of
motivation and blunted emotions, and cognitive impair-
ment mainly due to deficits in working memory and
attention [22]. Although symptoms of schizophrenia usu-
ally appear in the late second or third decade of life, it is
considered to be a neurodevelopmental mental disorder.
Both genetic and environmental factors contribute to the
development of schizophrenia, but a complete picture of
pathogenic events is still not clear. Alterations in glutamate
and dopamine neurotransmission seem to be the main
cause of the symptoms, but it is not known how these
abnormalities develop [87]. Treatments for schizophrenia
are limited and, in general, consist of drugs that act mainly
on positive symptoms. The introduction of chlorpromazine
in 1954 as a first compound for the treatment of schizo-
phrenia opened the era of psychopharmacology. Similar
drugs were developed in the 1950s and 1960s (typical
antipsychotics), finally giving the possibility of controlling
symptoms in schizophrenic patients and limiting behav-
ioral abnormalities. Although these molecules are known to
have different pharmacological actions [146], their anti-
psychotic effect is thought to be due to the inhibition of the
D2 dopamine receptor. However, severe side effects are
associated with these treatments, such as a strong sedative
action or extra-pyramidal motor control disabilities, lead-
ing to a syndrome per se. The subsequent development of
other antipsychotic therapies led to the discovery of dif-
ferent compounds (atypical antipsychotics), but with
similar mechanisms of action. These drugs prevent positive
symptoms, and, even if attenuated, they cause important
side effects, especially related to metabolic syndromes and
extrapyramidal symptoms [71]. Due to severe side effects,
the treatment with antipsychotics (typical or atypical) is
often associated with low compliance of the patient and
non-adherence to the therapy. In addition, patients develop
drug resistance. For these reasons, there is a real need for
new treatments involving novel targets with increased
efficacy and better tolerability. New therapies should also
aim at targeting negative symptoms and cognitive deficits,
and reducing the functional and social impairment, which
prevent schizophrenic patients from living a normal life
[71].
The role of NOX enzymes in the pathogenesis of
schizophrenia has been shown in two different experi-
mental animal models. By inducing schizophrenia-like
symptoms in mice with subchronic administration of
subanesthetic doses of ketamine, Behrens and colleagues
first demonstrated that NOX2-dependent ROS production
induces a loss of parvalbumin in interneurons [11, 12].
Parvalbumin is a Ca2? binding protein, which normally
regulates activity of GABAergic interneurons, thereby
modulating the glutamatergic transmission. Decrease in
parvalbumin expression has been detected in the brain of
schizophrenic patients, suggesting an alteration in the
control of excitatory glutamatergic neurotransmission,
possibly related to schizophrenia symptoms [86]. By ana-
lyzing the acute effects of ketamine on mouse behavior and
neurotransmission, it has been found that an increased
production of ROS by NOX2 can be determinant to ini-
tially trigger the increase in glutamate and dopamine
release [52, 143]. In contrast, the repetitive ketamine
exposure leads to adaptive alteration of the post-synaptic
NMDA receptor [143], possibly as a consequence of par-
valbumin decrease [76]. The beneficial effect of NOX2
inhibition is not limited to the psychosis induced by keta-
mine, as similar observations were made in a model of
social isolation in the rat. In rats grown in social isolation
for 7 weeks after weaning, NOX2 is up-regulated con-
comitantly with behavioral alterations, and signs of
oxidative stress and loss of parvalbumin. Treatment with
apocynin, a non-specific NOX inhibitor, was able to pre-
vent all these effects [136]. Since the social isolation of
young rats after weaning induces a prolonged stress during
the development of the CNS [83], these findings show in
two unrelated models using two different species that
NOX2-dependent generation of ROS can play a role in the
pathogenesis of schizophrenia. However, at this stage,
although signs of oxidative stress are known in schizo-
phrenic patients, NOX2 expression pattern in post mortem
specimens or even increased NOX2 activity in peripheral
leukocytes has so far not been documented. NOX inhibi-
tion in animal models of psychosis does not only
completely prevent behavioral changes but also blunts
signs of oxidative stress as well as the histopathological
and neurochemical alterations observed in these models.
Development of CNS-targeted NOX inhibitors therefore
represents an extremely promising alternative approach to
existing therapies currently used in the treatment of psy-
chotic disorders.
Stroke
Stroke is a leading cause of death and permanent disability
worldwide. The majority of strokes are ischemic, due to the
occlusion of a vessel in the brain. Intervention in these
cases is mainly based on enzymatic or mechanical removal
of the occlusion to restore blood flow. Even if beneficial,
this treatment can be performed in patients only 3–4 h after
the occurrence of stroke, because of the associated severe
risk of inducing a hemorrhage [99]. Since it is difficult to
rescue the infarcted area, possible therapies are designed to
reduce further development of tissue damage and cognitive
Pharmacological targeting of NOX in the CNS 2393
123
T
ab
le
2
A
p
o
cy
n
in
u
se
in
v
iv
o
in
ex
p
er
im
en
ta
l
C
N
S
d
is
o
rd
er
m
o
d
el
s
D
is
ea
se
M
o
d
el
S
p
ec
ie
s
D
o
se
W
ay
/d
u
ra
ti
o
n
ad
m
in
T
h
er
ap
eu
ti
c
b
en
efi
t
R
ef
er
en
ce
s
A
D
T
ra
n
sg
en
ic
m
ic
e
o
v
er
ex
p
re
ss
in
g
h
u
m
an
A
P
P
w
it
h
tw
o
m
u
ta
ti
o
n
s
(T
g
1
9
9
5
9
)
M
ic
e
3
0
0
m
g
/k
g
In
th
e
d
ri
n
k
in
g
w
at
er
fr
o
m
1
to
5
m
o
n
th
s
o
f
ag
e
N
o
im
p
ro
v
em
en
t
o
f
b
eh
av
io
r
an
d
n
eu
ro
p
at
h
o
lo
g
ic
si
g
n
s
(a
m
y
lo
id
d
ep
o
si
ti
o
n
,
m
ic
ro
g
li
o
si
s
an
d
ta
u
p
h
o
sp
h
o
ry
la
ti
o
n
)
[3
4
]
T
ra
n
sg
en
ic
m
ic
e
o
v
er
ex
p
re
ss
in
g
h
u
m
an
A
P
P
w
it
h
th
e
S
w
ed
is
h
an
d
L
o
n
d
o
n
m
u
ta
ti
o
n
s
h
A
P
P
(7
5
1
)(
S
L
)
M
ic
e
1
0
m
g
/k
g
D
ai
ly
g
av
ag
e
fr
o
m
4
to
8
m
o
n
th
s
o
f
ag
e
R
ed
u
ce
d
p
la
q
u
e
si
ze
an
d
m
ic
ro
g
li
a
p
ro
li
fe
ra
ti
o
n
in
th
e
co
rt
ex
[9
5
]
P
D
S
eq
u
en
ti
al
in
je
ct
io
n
s
i.
p
o
f
p
ar
aq
u
at
(1
0
m
g
/k
g
/3
d
ay
s)
M
ic
e
2
0
0
m
g
/k
g
i.
p
.
D
ec
re
as
e
in
d
o
p
am
in
er
g
ic
n
eu
ro
n
al
lo
ss
an
d
m
ic
ro
g
li
a
p
ro
li
fe
ra
ti
o
n
in
th
e
su
b
st
an
ti
a
n
ig
ra
[3
1
]
A
L
S
S
O
D
1
G
9
3
A
S
O
D
1
G
9
3
A
tr
an
sg
en
ic
m
ic
e
3
0
,
1
5
0
,
an
d
3
0
0
m
g
/k
g
/
d
ay
In
d
ri
n
k
in
g
w
at
er
st
ar
ti
n
g
at
d
ay
1
4
o
f
ag
e
In
cr
ea
se
d
su
rv
iv
al
b
y
5
6
,
8
0
an
d
1
1
3
d
ay
s
re
sp
ec
ti
v
el
y
[5
4
]
1
5
0
,
3
0
0
an
d
7
5
0
m
g
/k
g
/
d
ay
In
d
ri
n
k
in
g
w
at
er
st
ar
ti
n
g
at
d
ay
2
1
an
d
1
0
0
o
f
ag
e
N
o
in
cr
ea
se
d
su
rv
iv
al
fo
r
an
y
tr
ea
tm
en
t
p
ro
to
co
l
[1
5
2
]
1
5
0
m
g
/k
g
W
ay
n
o
t
sp
ec
ifi
ed
,
st
ar
ti
n
g
at
d
ay
5
0
o
f
ag
e
In
cr
ea
se
d
su
rv
iv
al
b
y
5
d
ay
s
[8
9
]
S
ch
iz
o
p
h
re
n
ia
i.
p
.
su
b
an
es
th
et
ic
k
et
am
in
e
in
je
ct
io
n
(3
0
m
g
/k
g
)
o
n
tw
o
co
n
se
cu
ti
v
e
d
ay
s
at
ar
o
u
n
d
4
p
m
C
5
7
B
L
/6
J
m
ic
e
5
m
g
/k
g
/d
ay
P
er
o
s
in
th
e
d
ri
n
k
in
g
w
at
er
fo
r
a
to
ta
l
o
f
se
v
en
d
ay
s
b
ef
o
re
k
et
am
in
e
in
ec
ti
o
n
s
D
ec
re
as
ed
o
x
id
at
iv
e
st
re
ss
an
d
lo
ss
o
f
p
ar
v
al
b
u
m
in
[1
1
]
P
o
st
-w
ea
n
in
g
so
ci
al
is
o
la
ti
o
n
fo
r
7
w
ee
k
s
W
is
ta
r
ra
ts
5
m
g
/k
g
/d
ay
P
er
o
s
in
d
ri
n
k
in
g
w
at
er
fo
r
7
w
ee
k
s
D
ec
re
as
ed
o
x
id
at
iv
e
st
re
ss
,
p
re
v
en
te
d
p
ar
v
al
b
u
m
in
lo
ss
an
d
b
eh
av
io
u
ra
l
al
te
ra
ti
o
n
s
[1
3
6
]
Is
ch
em
ic
st
ro
k
e
2
h
M
C
A
o
cc
lu
si
o
n
w
it
h
a
p
o
ly
-L
-l
y
si
n
e-
co
at
ed
m
o
n
o
fi
la
m
en
t
su
tu
re
fo
ll
o
w
ed
b
y
2
2
h
re
p
er
fu
si
o
n
C
5
7
B
L
/6
J
m
ic
e
2
.5
m
g
/k
g
N
O
T
at
h
ig
h
er
d
o
se
s
o
f
3
.7
5
an
d
5
m
g
/k
g
i.
v
.
3
0
m
in
b
ef
o
re
re
p
er
fu
si
o
n
Im
p
ro
v
ed
n
eu
ro
lo
g
ic
al
fu
n
ct
io
n
,
re
d
u
ce
d
in
fa
rc
t
v
o
lu
m
e,
an
d
re
d
u
ce
d
th
e
in
ci
d
en
ce
o
f
ce
re
b
ra
l
h
em
o
rr
h
ag
e
[1
5
0
]
2
h
M
C
A
o
cc
lu
si
o
n
w
it
h
in
tr
al
u
m
in
al
fi
la
m
en
t
fo
ll
o
w
ed
b
y
2
4
h
re
p
er
fu
si
o
n
C
5
7
B
L
/6
J
m
ic
e
2
.5
m
g
/k
g
i.
v
.
at
th
e
o
n
se
t
o
f
re
p
er
fu
si
o
n
R
ed
u
ce
d
in
fa
rc
t
v
o
lu
m
e,
b
et
te
r
n
eu
ro
lo
g
ic
al
fu
n
ct
io
n
,
le
ss
B
B
B
d
is
ru
p
ti
o
n
an
d
h
em
o
rr
h
ag
e,
d
ec
re
as
ed
M
M
P
-9
ex
p
re
ss
io
n
an
d
p
re
v
en
ti
o
n
o
f
ti
g
h
t
ju
n
ct
io
n
p
ro
te
in
lo
ss
[1
6
5
]
1
.5
h
M
C
A
o
cc
lu
si
o
n
w
it
h
a
n
y
lo
n
m
o
n
o
fi
la
m
en
t
(4
-0
)
fo
ll
o
w
ed
b
y
2
h
re
p
er
fu
si
o
n
S
p
ra
g
u
e–
D
aw
le
y
ra
ts
5
0
m
g
/k
g
i.
p
.
in
je
ct
io
n
3
0
m
in
p
ri
o
r
to
re
p
er
fu
si
o
n
R
ed
u
ce
d
N
O
X
ac
ti
v
it
y
,
su
p
er
o
x
id
e
le
v
el
s
an
d
in
fa
rc
t
si
ze
[1
4
9
]
0
.5
h
M
C
A
o
cc
lu
si
o
n
fo
ll
o
w
ed
b
y
2
3
.5
h
re
p
er
fu
si
o
n
C
5
7
B
l/
6
J
m
ic
e
2
.5
m
g
/k
g
i.
p
.
in
je
ct
io
n
0
.5
h
b
ef
o
re
is
ch
ae
m
ia
R
ed
u
ce
d
to
ta
l
in
fa
rc
t
v
o
lu
m
e,
n
eu
ro
lo
g
ic
al
im
p
ai
rm
en
t,
su
p
er
o
x
id
e
p
ro
d
u
ct
io
n
an
d
m
o
rt
al
it
y
[6
6
]
7
5
m
in
M
C
A
o
cc
lu
si
o
n
u
si
n
g
a
6
-0
co
at
ed
su
tu
re
fo
ll
o
w
ed
b
y
re
p
er
fu
si
o
n
C
5
7
B
L
/6
J
m
ic
e
4
m
g
/k
g
i.
p
.
in
je
ct
io
n
5
m
in
b
ef
o
re
su
tu
re
w
it
h
d
ra
w
al
R
ed
u
ce
d
o
x
id
at
iv
e
st
re
ss
,
5
0
%
le
ss
b
ra
in
in
fa
rc
ti
o
n
an
d
7
0
%
le
ss
cl
ea
v
ed
sp
ec
tr
in
[2
7
]
9
0
m
in
M
C
A
o
cc
lu
si
o
n
w
it
h
2
2
.5
h
re
p
er
fu
si
o
n
S
p
ra
g
u
e–
D
aw
le
y
ra
ts
3
0
m
g
/k
g
i.
p
.
in
je
ct
io
n
1
h
b
ef
o
re
th
e
o
n
se
t
o
f
M
C
A
O
R
ed
u
ce
d
th
e
M
M
P
-9
in
cr
ea
se
,
B
B
B
d
am
ag
e
b
ra
in
ed
em
a,
an
d
N
O
X
ac
ti
v
it
y
[9
1
]
2
h
M
C
A
o
cc
lu
si
o
n
w
it
h
a
4
–
0
n
y
lo
n
m
o
n
o
fi
la
m
en
t
fo
ll
o
w
ed
b
y
2
2
h
re
p
er
fu
si
o
n
W
is
ta
r
ra
ts
5
m
g
/k
g
i.
p
.
in
je
ct
io
n
5
m
in
b
ef
o
re
re
p
er
fu
si
o
n
R
ed
u
ct
io
n
in
in
fa
rc
t
si
ze
,
in
fl
am
m
at
io
n
an
d
ce
ll
u
la
r
d
ea
th
[4
5
]
2394 S. Sorce et al.
123
T
ab
le
2
A
p
o
cy
n
in
u
se
in
v
iv
o
in
ex
p
er
im
en
ta
l
C
N
S
d
is
o
rd
er
m
o
d
el
s
D
is
ea
se
M
o
d
el
S
p
ec
ie
s
D
o
se
W
ay
/d
u
ra
ti
o
n
ad
m
in
T
h
er
ap
eu
ti
c
b
en
efi
t
R
ef
er
en
ce
s
M
C
A
o
cc
lu
si
o
n
w
it
h
a
si
li
co
n
e-
co
at
ed
8
-0
m
o
n
o
fi
la
m
en
t
fo
r
2
h
fo
ll
o
w
ed
b
y
2
2
h
re
p
er
fu
si
o
n
C
5
7
B
L
/6
m
ic
e
0
.4
,
4
,
an
d
4
0
m
g
/k
g
i.
v
.
1
h
b
ef
o
re
in
d
u
ct
io
n
o
f
M
C
A
O
4
0
m
g
/k
g
p
re
v
en
te
d
B
B
B
d
is
ru
p
ti
o
n
[7
0
]
9
0
m
in
M
C
A
o
cc
lu
si
o
n
fo
ll
o
w
ed
b
y
1
,
4
,
8
,
2
4
h
re
p
er
fu
si
o
n
S
p
ra
g
u
e–
D
aw
le
y
ra
ts
(7
w
ee
k
s
o
ld
)
5
m
g
/k
g
i.
p
.
3
0
m
in
b
ef
o
re
in
d
u
ct
io
n
o
f
M
C
A
O
an
d
5
m
in
af
te
r
re
p
er
fu
si
o
n
A
tt
en
u
at
ed
p
ro
te
in
ca
rb
o
n
y
la
ti
o
n
in
th
e
p
o
st
sy
n
ap
ti
c
d
en
si
ty
p
ro
te
in
s
an
d
ce
re
b
ra
l
in
fa
rc
t
v
o
lu
m
e
[1
1
1
]
O
cc
lu
si
o
n
o
f
b
o
th
co
m
m
o
n
ca
ro
ti
d
ar
te
ri
es
M
o
n
g
o
li
an
g
er
b
il
s
5
m
g
/k
g
i.
p
.
3
0
m
in
b
ef
o
re
is
ch
em
ia
A
tt
en
u
at
ed
o
x
id
at
iv
e
st
re
ss
,
n
eu
ro
n
al
d
eg
en
er
at
io
n
an
d
g
li
a
ac
ti
v
at
io
n
[1
6
0
]
M
C
A
o
cc
lu
si
o
n
w
it
h
ti
ss
u
e
p
la
sm
in
o
g
en
ac
ti
v
at
o
r
Y
o
u
n
g
(3
-
4
m
o
n
th
s)
an
d
ag
ed
(1
8
-
2
0
m
o
n
th
s)
ra
ts
5
m
g
/k
g
i.
p
.
3
0
m
in
b
ef
o
re
in
d
u
ct
io
n
o
f
M
C
A
O
in
ag
ed
ra
ts
in
cr
ea
se
d
m
o
rt
al
it
y
ra
te
an
d
fa
il
ed
to
im
p
ro
v
e
th
e
fu
n
ct
io
n
al
o
u
tc
o
m
e,
to
ta
l
in
fa
rc
t
v
o
lu
m
e,
ed
em
a
fo
rm
at
io
n
,
an
d
B
B
B
p
er
m
ea
b
il
it
y
[7
3
]
T
ra
n
si
en
t
g
lo
b
al
ce
re
b
ra
l
is
ch
em
ia
in
d
u
ce
d
b
y
b
il
at
er
al
co
m
m
o
n
ca
ro
ti
d
ar
te
ry
o
cc
lu
si
o
n
fo
r
2
2
m
in
fo
ll
o
w
ed
b
y
3
,
6
an
d
7
2
h
re
p
er
fu
si
o
n
C
5
7
B
L
/6
2
.5
m
g
/k
g
i.
v
.
1
5
m
in
b
ef
o
r
is
ch
em
ia
A
tt
en
u
at
ed
o
x
id
at
iv
e
in
ju
ry
,
m
ic
ro
g
li
al
ac
ti
v
at
io
n
,
an
d
n
eu
ro
n
al
d
ea
th
[1
6
7
]
1
h
M
C
A
fo
ll
o
w
ed
b
y
2
4
h
re
p
er
fu
si
o
n
C
5
7
B
L
/6
m
ic
e
4
m
g
/k
g
i.
v
.
1
h
af
te
r
M
C
A
O
N
o
re
d
u
ct
io
n
o
f
in
fa
rc
t
si
ze
[7
7
]
H
em
o
rr
h
ag
ic
st
ro
k
e
E
n
d
o
v
as
cu
la
r
p
er
fo
ra
ti
o
n
o
f
th
e
ri
g
h
t
an
te
ri
o
r
ce
re
b
ra
l
ar
te
ry
R
at
s
5
0
m
g
/k
g
i.
p
.
in
je
ct
io
n
3
ti
m
es
d
ai
ly
fo
r
2
d
ay
s
E
n
la
rg
ed
b
as
il
ar
ar
te
ry
d
ia
m
et
er
,
re
d
u
ce
d
n
eu
ro
lo
g
ic
al
d
efi
ci
ts
,
d
ec
re
as
ed
N
O
X
ac
ti
v
it
y
an
d
su
p
er
o
x
id
e
p
ro
d
u
ct
io
n
[1
7
2
]
In
tr
ac
er
eb
ra
l
h
ae
m
o
rr
h
ag
e
R
at
s
3
,
1
0
an
d
3
0
m
g
/k
g
i.
p
.
2
h
af
te
r
h
ae
m
o
rr
h
ag
e
N
o
n
eu
ro
p
ro
te
ct
iv
e
ef
fe
ct
[1
5
1
]
G
ly
ce
ro
l-
in
d
u
ce
d
in
tr
av
en
tr
ic
u
la
r
h
em
o
rr
h
ag
e
(I
V
H
)
in
p
re
m
at
u
re
ly
d
el
iv
er
ed
(E
2
9
)
ra
b
b
it
p
u
p
s
b
y
in
tr
ap
er
it
o
n
ea
l
in
fu
si
o
n
o
f
5
0
%
g
ly
ce
ro
l
(6
.5
g
/k
g
)
so
lu
ti
o
n
2
h
af
te
r
b
ir
th
R
ab
b
it
2
.5
m
g
/k
g
p
er
d
o
se
i.
v
.
in
je
ct
io
n
s
at
3
an
d
1
2
h
af
te
r
IV
H
R
ed
u
ce
d
R
O
S
g
en
er
at
io
n
an
d
ce
ll
d
ea
th
[1
7
4
]
Is
ch
em
ic
b
ra
in
in
ju
ry
as
so
ci
at
ed
w
it
h
h
y
p
er
g
li
ce
m
ia
T
ra
n
si
en
t
b
il
at
er
al
co
m
m
o
n
ca
ro
ti
d
ar
te
ry
o
cc
lu
si
o
n
s
an
d
h
y
p
er
g
ly
ce
m
ia
C
5
7
B
l/
6
J
m
ic
e
1
5
m
g
/K
g
i.
p
.
in
je
ct
io
n
b
ef
o
re
re
p
er
fu
si
o
n
D
ec
re
as
ed
n
eu
ro
n
al
su
p
er
o
x
id
e
p
ro
d
u
ct
io
n
an
d
d
ea
th
[1
4
8
]
Is
ch
em
ic
b
ra
in
in
ju
ry
as
so
ci
at
ed
w
it
h
ch
ro
n
ic
al
co
h
o
l
co
n
su
m
p
ti
o
n
L
iq
u
id
d
ie
t
w
it
h
al
co
h
o
l
(6
.4
%
v
/v
)
fo
r
8
w
ee
k
s,
2
-h
m
id
d
le
ce
re
b
ra
l
ar
te
ry
o
cc
lu
si
o
n
fo
ll
o
w
ed
b
y
2
4
-h
re
p
er
fu
si
o
n
S
p
ra
g
u
e–
D
aw
le
y
ra
ts
A
cu
te
:
5
m
g
/k
g
ch
ro
n
ic
:
7
.5
m
g
/k
g
/
d
ay
A
cu
te
:
i.
p
.
3
0
m
in
b
ef
o
re
M
C
A
O
C
h
ro
n
ic
:
p
er
o
s,
4
w
ee
k
s
p
ri
o
r
to
M
C
A
O
B
o
th
tr
ea
tm
en
ts
re
d
u
ce
d
in
fa
rc
t
v
o
lu
m
e,
im
p
ro
v
ed
n
eu
ro
lo
g
ic
al
o
u
tc
o
m
e,
at
te
n
u
at
ed
su
p
er
o
x
id
e
p
ro
d
u
ct
io
n
in
al
co
h
o
l-
fe
d
ra
ts
[1
7
1
]
Is
ch
em
ic
b
ra
in
in
ju
ry
as
so
ci
at
ed
w
it
h
h
y
p
er
te
n
si
o
n
T
w
o
re
n
al
ar
te
ri
es
w
er
e
co
n
st
ri
ct
ed
b
il
at
er
al
ly
w
it
h
tw
o
ri
n
g
-s
h
ap
ed
si
lv
er
cl
ip
s
S
tr
o
k
e-
p
ro
n
e
re
n
o
v
as
cu
la
r
h
y
p
er
te
n
si
v
e
ra
ts
1
.5
m
m
o
l/
L
P
er
o
s
in
th
e
d
ri
n
k
in
g
w
at
er
fo
r
2
8
d
ay
s
b
eg
in
n
in
g
o
n
th
e
5
th
w
ee
k
af
te
r
th
e
o
p
er
at
io
n
D
ec
re
as
e
in
th
e
ex
p
re
ss
io
n
o
f
p
2
2
p
h
o
x
p
ro
te
in
an
d
fi
b
ro
n
ec
ti
n
le
v
el
s
in
th
e
ce
re
b
ra
l
v
as
cu
la
tu
re
[3
2
]
Is
ch
em
ic
b
ra
in
in
ju
ry
as
so
ci
at
ed
w
it
h
ex
ce
ss
sa
lt
co
n
su
m
p
ti
o
n
8
%
so
d
iu
m
d
ie
t
fr
o
m
1
1
w
ee
k
s
o
f
ag
e
d
u
ri
n
g
1
,
2
,
o
r
4
w
ee
k
s
S
tr
o
k
e-
p
ro
n
e
sp
o
n
ta
n
eo
u
sl
y
h
y
p
er
te
n
si
v
e
ra
ts
0
.6
m
m
o
l/
k
g
p
er
d
ay
P
er
o
s
in
th
e
d
ri
n
k
in
g
w
at
er
fo
r
4
w
ee
k
s
R
ed
u
ce
d
o
x
id
at
iv
e
st
re
ss
,
ce
ll
d
ea
th
an
d
st
ro
k
e
in
ci
d
en
ce
[1
6
6
]
Pharmacological targeting of NOX in the CNS 2395
123
T
a
b
le
2
co
n
ti
n
u
ed
D
is
ea
se
M
o
d
el
S
p
ec
ie
s
D
o
se
W
ay
/d
u
ra
ti
o
n
ad
m
in
T
h
er
ap
eu
ti
c
b
en
efi
t
R
ef
er
en
ce
s
N
eo
n
at
al
h
y
p
o
x
ic
-
is
ch
em
ic
in
ju
ry
O
n
p
o
st
n
at
al
d
ay
7
,
le
ft
co
m
m
o
n
ca
ro
ti
d
ar
te
ry
w
as
ca
u
te
ri
ze
d
o
v
er
a
le
n
g
th
o
f
5
m
m
.
2
to
4
h
af
te
r
su
rg
er
y
,
th
e
ra
ts
w
er
e
ex
p
o
se
d
to
1
0
0
%
o
x
y
g
en
at
3
7
C
fo
r
2
h
W
is
ta
r
ra
ts
4
m
g
/k
g
i.
p
.
in
je
ct
io
n
,
fi
rs
t
d
o
se
fo
ll
o
w
in
g
h
y
p
er
o
x
ia
an
d
ag
ai
n
th
e
fo
ll
o
w
in
g
m
o
rn
in
g
In
cr
ea
se
d
N
O
an
d
re
d
u
ce
d
O
2
-
[3
7
]
H
u
n
ti
n
g
to
n
d
is
ea
se
In
tr
as
tr
ia
ta
l
in
je
ct
io
n
o
f
q
u
in
o
li
n
ic
ac
id
(Q
U
IN
)
2
4
0
n
m
o
l/
u
l
W
is
ta
r
ra
ts
5
m
g
/k
g
i.
p
.
3
0
m
in
b
ef
o
re
an
d
1
h
af
te
r
Q
U
IN
in
je
ct
io
n
o
r
o
n
ly
3
0
m
in
af
te
r
Q
U
IN
in
je
ct
io
n
D
ec
re
as
ed
li
p
id
p
er
o
x
id
at
io
n
,
ci
rc
li
n
g
b
eh
av
io
r,
an
d
h
is
to
lo
g
ic
al
d
am
ag
e
[9
6
]
In
su
li
n
-i
n
d
u
ce
d
h
y
p
o
g
ly
ce
m
ia
H
y
p
o
g
li
ce
m
ia
fo
ll
o
w
ed
b
y
g
lu
co
se
re
p
er
fu
si
o
n
(i
n
fu
si
o
n
o
f
5
0
%
g
lu
co
se
in
K
re
b
s-
H
en
se
le
it
b
u
ff
er
)
S
p
ra
g
u
e–
D
aw
le
y
ra
ts
1
5
m
g
/k
g
i.
p
.
in
je
ct
io
n
b
ef
o
re
th
e
st
ar
t
o
f
g
lu
co
se
re
p
er
fu
si
o
n
R
ed
u
ce
d
n
eu
ro
n
al
d
ea
th
[1
4
7
]
N
M
D
A
re
ce
p
to
r-
d
ep
en
d
en
t
ex
ci
to
to
x
ic
it
y
In
je
ct
io
n
s
o
f
6
n
m
o
l
o
f
N
M
D
A
in
th
e
ri
g
h
t
h
ip
p
o
ca
m
p
u
s
C
5
7
B
L
/6
m
ic
e
1
5
m
g
/k
g
i.
p
.
in
je
ct
io
n
2
0
–
3
0
m
in
b
ef
o
re
th
e
N
M
D
A
in
je
ct
io
n
s
P
re
v
en
te
d
su
p
er
o
x
id
e
p
ro
d
u
ct
io
n
an
d
n
eu
ro
n
al
d
ea
th
[2
0
]
E
p
il
ep
sy
P
il
o
ca
rp
in
e
in
je
ct
io
n
s
in
h
ip
p
o
ca
m
p
u
s
W
is
ta
r
ra
ts
1
0
m
g
/k
g
In
th
e
d
ri
n
k
in
g
w
at
er
7
d
ay
s
p
ri
o
r
to
in
d
u
ct
io
n
o
f
st
at
u
s
ep
il
ep
ti
cu
s
D
ec
re
as
ed
R
O
S
p
ro
d
u
ct
io
n
an
d
n
eu
ro
d
eg
en
er
at
io
n
[1
2
2
]
A
n
x
ie
ty
l-
b
u
th
io
n
in
e-
(S
,R
)-
su
lf
o
x
im
in
e
(B
S
O
,
3
0
0
m
g
/k
g
i.
p
.)
4
8
an
d
2
4
h
b
ef
o
re
b
eh
av
io
ra
l
te
st
in
g
IC
R
m
ic
e
3
m
g
/k
g
i.
p
.
in
je
ct
io
n
3
0
m
in
b
ef
o
re
ea
ch
B
S
O
tr
ea
tm
en
t
R
ed
u
ce
d
an
x
ie
ty
-l
ik
e
b
eh
av
io
ra
l
[1
0
1
]
O
b
st
ru
ct
iv
e
sl
ee
p
ap
n
ea
L
o
n
g
-t
er
m
in
te
rm
it
te
n
t
h
y
p
o
x
ia
C
5
7
B
L
/6
J
m
ic
e
3
m
g
/k
g
/d
ay
S
u
b
cu
ta
n
eo
u
sl
y
b
y
w
ay
o
f
m
ic
ro
o
sm
o
ti
c
p
u
m
p
fo
r
8
w
ee
k
s
C
o
n
fe
rr
ed
re
si
st
an
ce
to
h
y
p
er
so
m
n
o
le
n
ce
,
re
d
u
ce
d
o
x
id
at
iv
e
d
am
ag
e
an
d
ca
th
ec
o
la
m
in
er
g
ic
n
eu
ro
n
d
ea
th
in
w
ak
e-
ac
ti
v
e
b
ra
in
re
g
io
n
s
[1
6
9
,
1
7
3
]
L
o
n
g
-t
er
m
in
te
rm
it
te
n
t
h
y
p
o
x
ia
S
p
ra
g
u
e–
D
aw
le
y
ra
ts
3
m
g
/k
g
/d
ay
in
5
0
u
l
o
f
0
.9
%
sa
li
n
e
In
tr
ag
as
tr
ic
al
ly
3
d
ay
s
b
ef
o
re
A
m
el
io
ra
ti
o
n
o
f
sp
at
ia
l
le
ar
n
in
g
d
efi
ci
ts
,
d
ec
re
as
ed
o
x
id
at
iv
e
st
re
ss
an
d
ap
o
p
to
si
s
[6
0
]
2396 S. Sorce et al.
123
impairment associated with the ischemic insult. Another
approach is to prevent the occurrence of stroke in subjects
at risk [134].
Considerable variation in the outcome of ischemic
stroke using transient middle cerebral artery occlusion
(tMCAO) in NOX-deficient animals was observed. In an
early study, Walder et al. [157] described that the infarct
volume was reduced by approximately 50 % in NOX2-
deficient mice after 2 h transient ischemia followed by
22 h reperfusion. These observations were further con-
firmed in different studies using similar ischemia–
reperfusion approaches ranging from 30 to 75 to 120 min
ischemia followed by 22–24 h reperfusion [27, 66, 70]. A
recent study repeated exactly the study by Walder et al.
[157] confirming the protective effect of NOX2 deficiency
[165]. For NOX1-deficient mice, the time of ischemia
appears to be critical for the switch between a protective or
a deleterious effect of NOX1 activity. NOX1 deficiency
decreased infarct size when 60 min ischemia was applied,
while no differences were observed with occlusion time
was 2 h or more [70]. In a model of 30 min ischemia
followed by 24 h reperfusion, NOX1-deficient mice
showed no difference in neurological score, total or sub-
cortical cerebral infarct volume, or edema volume as
compared to WT. However, cortical infarct volume was
approximately fourfold greater in brains of NOX1-KO
versus WT mice [66]. Moreover, a recent study using
60 min ischemia followed by 24 h reperfusion showed
impressive protection in NOX4-deficient mice, but no
difference in either NOX1- or NOX2-deficient mice. Sub-
stantial decrease of infarct size was also observed in
NOX4-deficient mice when no reperfusion was applied
24 h after ischemia, while no data are available for NOX1-
or NOX2-deficient mice for this model [77]. Such dis-
crepancies are unfortunately not rare in rodent models of
ischemia–reperfusion, as experimental details can affect
the lesion in either beneficial or detrimental way, because
tiny differences in the cerebral vasculature between mouse
strains and surgical technique can account for important
changes in infarct severity, such as body temperature
control, blood pressure and blood monitoring, anesthetic
used, and surgery time [36, 88]. In order to reconcile and
understand these divergent data, some approaches can be
proposed: (1) genotypic homogeneity of the strains could
be verified, (2) a single operator could perform blindly both
transient and permanent ischemia, (3) different times of
ischemia could be tested for different knock-outs, and (4)
permanent occlusion models could be used and neuronal
cell death followed up at different time points as a relevant
model of stroke. Although a direct neurotoxic role of ROS
is possible, the possible mechanism played by NOX in
stroke is still unclear, and a role in the BBB integrity and
cerebrovascular permeability is emerging [41].
Obstructive sleep apnea syndrome (OSAS)
Obstructive sleep apnea is a respiratory disturbance char-
acterized by recurrent occlusions of the upper airways and
reduction in oxygen availability during sleep followed by
sudden awakening and reoxygenation. The underlying
neuropathological events of obstructive sleep apnea are
still unclear, but it is known that intermittent hypoxia
episodes cause behavioral alterations and cognitive
impairments [9].
OSAS often affects obese patients, due to fat deposition
in the parapharyngeal space, in the tongue, and under the
mandible, reducing the upper airway caliber and predis-
posing them to breathing disorders during sleep [51].
The main remedy for OSAS consists of the application
of devices to induce a nocturnal continuous positive airway
pressure (CPAP), but this is poorly accepted by patients.
Surgery can also be considered in certain cases to defini-
tively remove the obstruction of upper airways. Otherwise,
weight loss in obese patients or avoidance of risk factors,
e.g., alcohol consumption, can be helpful to reduce the
occurrence of this respiratory disturbance [51].
The animal model of OSAS is called long-term inter-
mittent hypoxia (LTIH). It consists of the use of a particular
chamber with an oxygen/nitrogen delivery system which
automatically decreases the content of oxygen from 21 to
10 % at certain intervals for few seconds, inducing arterial
oxyhemoglobin saturation [169]. Excessive production of
ROS, neuronal death, and tissue damage are associated with
the cognitive dysfunctions in this model [161].
In animals submitted to LTIH, genetic depletion of
NOX2 (knock-out mice) or pharmacological (apocynin)
inhibition of NOX2 reduced hypersomnolence and pre-
vented oxidative damage in the wake-active regions of the
brain [169, 173]. A recent report similarly shows that cog-
nitive deficits induced by recurrent hypoxia events during
sleep are mediated by excessive NOX2 activity [112].
In patients affected by OSAS, markers of inflammation
(interleukin-6) and oxidative stress (8-isoprostane) can be
detected in exhaled breath condensate [23]. Interestingly,
neutrophils (which mainly express NOX2) of OSAS
patients also show an enhanced production of superoxide
[137]. The presence of these signs of oxidative stress has
been mainly associated with the cardiovascular conse-
quences of the disease. However, in light of the results
obtained from animal models, it is possible that increase of
NOX2 activity also contributes to the cognitive decline.
Increased mRNA expression of p22phox was detected in
peripheral blood mononuclear cells of 107 subjects affec-
ted by OSAS. In addition, in these patients, a significantly
higher frequency of the C242T polymorphism in CYBB,
the gene coding for p22phox, a NOX subunit necessary for
the function of 4 NOX isoforms (NOX1-4), was detected as
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compared to 69 healthy subjects [90]. Altogether, these
findings suggest a potential for a NOX2-based therapy to
treat the neurological consequences of sleep-associated
breathing disorders.
Beneficial effect of NOX enhancement: potential CNS
indications
Neurological autoimmune diseases
Multiple sclerosis (MS) is an inflammatory disease leading
to myelin damage, which progresses to physical and cogni-
tive disabilities. Disease onset usually occurs in young adults
and affects 3 times more females than males. MS prevalence
ranges between 2 and 150 per 100,000, but MS is much more
common in northern Europe. MS takes several forms, with
new symptoms occurring either in discrete attacks (relapsing
forms) or slowly accumulating over time (progressive
forms). There is no known cure for MS. Available treatments
attempt to return function after an attack, prevent new
attacks, and prevent disability. Administration of b-inter-
feron 1a (Rebif) shows some beneficial effects in a subset
of patients, but, despite claims to the contrary, their ability to
modify disease course has not been clearly established [39].
Antibodies to a4-integrin (Natalizumab) suppress the
extravasation of lymphocytes into the CNS, but may trigger
progressive multifocal leukoencephalopathy. Inhibition of
the sphingosine-1-phosphate receptor (Fingolimod) results
in the sequestration of lymphocytes in lymph nodes. Use of
drugs which non-specifically suppress the immune system
(glucocorticoids and the antineoplastic agent mitoxantrone)
slows the progression of the disease but are associated with
harmful side effects.
Although autoimmunity is a primary trigger in MS
lesion formation, it is now widely accepted that immune-
mediated inflammation contributes to MS pathogenesis.
Thus, the role of inflammatory auto-reactive CD4-positive
T helper (Th) cells has been extensively proven in animal
models of MS [57, 168]. However, although oxidative
damage is a known feature of MS [153], ROS produced by
NOX2 have been shown to be anti-inflammatory in auto-
immune diseases. Indeed, low ROS generation by NOX2
appears to prevent autoimmune responses in the chronic
EAE model of MS [62]. NOX2-dependent ROS of antigen
presenting cells are a key regulator of T cell activation.
Interestingly, leukocyte ROS production correlates inver-
sely with disease severity in MS [110] and recurrent
Guillain Barre´ syndrome (GBS) [108, 109]. Recurrent GBS
is also mediated by autoimmunity and is caused by damage
to the myelin sheet of the peripheral nerves. Current
treatments of recurrent GBS consist of corticosteroids,
plasmapheresis, and intravenous immunoglobulins.
Due to the critical role played by NOX enzymes in CNS
pathological states, it is almost certain that other patholo-
gies where oxidative stress is known to regulate disease
progression will show beneficial effects of NOX inhibition
(e.g., epilepsy, HIV-mediated dementia, or Huntington
among others) or NOX enhancement in autoimmune dis-
eases, such as leukodystrophies or progressive multifocal
leukoencephalopathy.
Therapeutics targeting ROS and NOX enzymes
Antioxidants
In the case of schizophrenia, several clinical trials have
recently been made with Vitamin C, E, omega-3 fatty acids, or
N-acetyl cysteine, suggesting a certain efficacy of improving
the antioxidant defence as adjunctive to a primary antipsy-
chotic treatment [131]. Of particular note, parallel
administration of N-acetyl cysteine could also moderately
diminish negative symptoms, such as akathisia [16]. How-
ever, as for cardiovascular diseases, the use of antioxidant
therapies has led to contradictory and mostly disappointing
outcomes in clinical trials for CNS diseases [82], in spite of
promising results obtained in in vitro studies and in animal
models for AD [141], and other neuropathologies, such as
stroke [134] or ALS [10]. Failure of antioxidant treatments
should not necessarily preclude the search of therapies tar-
geting oxidative stress to treat neuropathologies because there
are numerous possible reasons for the apparent failure of
antioxidant therapies, including lack of specificity, potency,
and bioavailability of antioxidant drugs, poor trial design, or
lack of relevant biomarkers of oxidation. Such issues are
discussed in details elsewhere [19, 47]. Nevertheless, as of
today, the medical use of such an approach still awaits solid
evidence of therapeutic benefit. On the other hand, the con-
certed search and discovery of NOX inhibitors is only
emerging. Neuroprotective action of several compounds have
been described as acting on the NOX pathway, but they are
probably acting upstream of NOX and, therefore, are blocking
other pharmacological targets [29]. However, recently, sys-
tematic screenings of chemical libraries were performed and
have identified new chemical entities targeting NOX enzymes
[18, 46, 80]. Although peptidic and siRNAs have been
designed to target NOX enzymes, we will only describe small
molecules that are currently described as NOX inhibitors.
Natural compounds
Apocynin
Apocynin or acetovanillone (MW 166.174) is a natural
organic compound widely used as a NOX inhibitor in
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models involving NOX enzymes [144], and has been
shown to be beneficial in numerous models of CNS dis-
eases at different doses and types of administration
(summarized in Table 2). However, the use of this mole-
cule as a NOX inhibitor remains controversial as its mode
of action is thought to be mostly through oxidant scav-
enging activity, although formation of an apocynin dimer
(diapocynin) accounts for NOX2 inhibition through the
activity of a peroxidase, such as the myeloperoxidase of
leukocytes [145, 56]. Surprisingly, for such a compound
which seems to represent a panacea for a large panel of
diseases, few studies of its bioavailability in vivo are
available. One study showed that, following single intra-
peritoneal injection (5 mg/kg), apocynin was detected in
the brain, but in a glycosylated form, while no diapocynin
could be detected [159]. However, another study showed a
contrary result following chronic oral treatment (150 and
300 mg/kg/day for above 100 days): no glycosylation, but
conversion of apocynin into diapocynin was detected in the
brain and spinal cord [152]. In almost all studies described
in Table 2, the compound has been administered (in con-
centrations ranging from 0.4 to 300 mg/kg) as preventive
treatment ranging from more than 2 months before disease
onset in the case of ALS [54] to a few minutes before
ischemic stroke [27]. It is clear that a curative approach
would be more relevant, although the outcome of such
studies is sometimes disappointing, as for hemorrhagic
stroke [151]. In the case of ALS, chronic treatment with
apocynin in the drinking water led to extremely variable
results: a first study described an increase of survival
(113 days) in SODG93A mice, a real hope for a potential
treatment in patients with ALS [54]. However, this
impressive outcome could not be repeated. A study fol-
lowing exactly the same treatment protocol showed no
benefit at all [152], while another study using a similar
protocol showed a modest increase of survival (5 days)
[89] (see Table 2). Interestingly, direct administration of
diapocynin (150 mg/kg/day) after disease onset showed an
8-day increase in mean survival of SODG93A mice [152].
As diapocynin is considered the active form of apocynin
[56], the rationale for NOX inhibition as a treatment for
ALS remains valid.
Discrepancies have also been described in studies with
chronic administration of apocynin (over 4 months) in
transgenic models of AD (see Table 2) [34, 95]. Differ-
ences in the dose, mouse model, and the age of the mice at
the beginning of the treatment may account for these
contrasting results. Future comprehensive PK/PD studies
for apocynin would greatly help researchers in the choice
of a dose and mode of administration. Due to such dis-
crepancies, lack of clear mechanism of action, lack of
specificity, high metabolism, previous failure of antioxi-
dant drugs, low potency on NOX enzymes, and extensive
patenting status, apocynin has a low potential for devel-
opment by pharmaceutical companies [1]. Nevertheless,
apocynin shows several advantages, which could poten-
tially make it a therapeutic agent for CNS disorders: low
toxicity, oral bioavailability, high potency in neuropathol-
ogies, and impact on surrogate markers of oxidative stress
in phase I clinical studies following aerosol administration
[123, 144]. Therefore, future studies associating apocynin
bioavailability (PK/PD) with real therapeutic benefit in
controlled preclinical trials after disease onset would pro-
vide proof of concept for a possible clinical development as
therapeutics for intractable CNS diseases.
Celastrol
Celastrol (MW 450.6) is a natural compound extracted from
the medicinal plant Tripterygium wilfordii, which has
recently been shown to be a bone fide NOX inhibitor as it
blocks within minutes both the increase of superoxide and
hydrogen peroxide (the product of the reaction calatysed by
NOX enzymes) and the decrease of its substrate, i.e. oxygen
[68]. Although celastrol has only recently been identified as a
NOX inhibitor, its neuroprotective properties have been
established several years ago. Injection of celastrol (2 and
8 mg/kg/day) improved survival of SODG93A mice by 9.4
and 13 %, respectively [74], improved dopaminergic neuron
survival in the MPTP model of PD (3 mg/kg, i.p before and
after MPTP injection) and with a dose of 3 mg/kg twice a day
for 5 days significantly decreased the striatal lesion volume
induced by 3-nitropropionic acid, a neurotoxin used to model
Huntington disease in rats [30]. In a transgenic model of AD
(Tg PS1/APPsw), celastrol (1 mg/kg i.p. for 4 days) and
chronic treatment (32 days) with celastrol (2.5 mg/kg/day
s.c. in a matrix-driven delivery pellet system) reduced the
levels of both soluble and insoluble amyloid beta peptides,
microglial activation, and amyloid beta plaque deposition
[118]. Recently, intraperitoneal administration of celastrol
improved the cognitive decline following major surgery in
old mice and reduced b-amyloid accumulation and s phos-
phorylation in the brain [158]. However, celastrol is a
complex molecule with numerous targets [72], and its use as
therapeutic awaits further study about its tolerability and
possible efficacy for CNS pathologies.
Phytol
In contrast to previous examples, phytol (3,7,11,15-tetra-
methyl-2-hexadecene-1-ol, MW 296.53) is a compound
which enhances NOX activity. Phytol has impressive effects
in vivo as it completely blunts autoimmune inflammation. In
the case of autoimmune disorders, phytol (i.p., but mostly
s.c.) therapeutic effect was first described in arthritis-prone
Ncf1 (DA) rats, which have a decreased NOX2-dependent
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oxidative burst. This compound has been shown to act by
increasing the phagocyte oxidative burst in vivo [61]. In an
acute model of Guillain Barre´, phytol treatment led to a
strong reduction in experimental allergic neuritis disease
severity and a lower number of IFN-c-secreting cells in late
disease stage [58]. The fact that phytol is an oil makes it an
unlikely candidate for development by the pharmaceutical
industry because of challenging SAR, pharmacokinetics, and
metabolism. Nevertheless, it represents a proof of concept for
therapies aiming at enhancing NOX activity.
Chemically synthesized molecules
Triazolopyrimidines
Several compounds developed by Vasopharm have been
described as NOX inhibitors (for review, see [69, 75, 162].
Recently, VAS2870l, a low-molecular-weight pharmacolog-
ical NADPH oxidase inhibitor was shown to inhibit NOX1,
NOX2, and NOX4, but this may be through an indirect mode
of action, at least for NOX2, because it does not block NOX2
activity in a semi-recombinant membrane assay [44]. When
2 mg VAS2870l solubilized in 10 % DMSO was injected
intrathecally 2 and 12 h after ischemia, brain infarct volumes
were reduced by 75 % compared to vehicle-treated mice
thereby improving neurological outcome and mice viability
[77]. However, this study failed to demonstrate efficacy of
apocynin (100 lg, i.v. 1 h before occlusion), thereby chal-
lenging other studies (Table 2). It was also the first report that
provides evidence for a potential use of NOX inhibitors in the
clinic for CNS diseases and suggests that investigation of
other compounds targeting NOX should be similarly per-
formed. Nevertheless, low solubility of this compound and
mode of administration (intrathecal) makes it an unlikely
candidate CNS drug for use in humans.
2-Acetylphenothiazine
Athough they have not yet been used in CNS disorders, it can
be expected that the compound 2-acetylphenothiazine
(ML171), which shows potent inhibitory activity (0.25 lM in
a cellular assay) on NOX1, but also NOX2, NOX3, and NOX4
in the low micromolar range [46], can be active in the CNS
because it belongs to the phenothiazine family of compounds,
which are known to cross the BBB and to act as antipsychotics,
but also act on other targets and are potent antioxidants [114].
3-Pyrazolopyridines
Recently, orally bioavailable small molecules developed
by Genkyotex show high potency against NOX1 and
NOX4 [43, 80] have shown high efficacy in animal models
[21, 138, 154]. However, at this stage, no information
about CNS permeability and efficacy in CNS disorders has
been documented.
4-Perhexiline
Perhexiline is primarily considered as a carnitine palmi-
toyltransferase inhibitor, and is used in patients to treat
angina pectoris [4]. Perhexiline has been known for a long
time to have NOX inhibitory activity [69], but a direct
action on the NOX2 isoform (IC50 = 13.2 lM in a semi-
recombinant assay) was recently demonstrated [44].
Because of oral bioavailability, perhexiline might be rec-
ommended as a NOX inhibitor to treat CNS diseases.
However, such an indication should, unfortunately, not be
recommended for this compound because in many cases it
induces drug-induced neuropathies [49, 133].
NOX inhibitors are currently developed by both academic
[18] and industrial laboratories, such as Shionogi or Mitsubi-
shi, for which only patents have been published (for review, see
[69, 75], but, unfortunately, BBB penetration or efficacy in
CNS indications has to our knowledge not been published.
Discussion and conclusion
Research and development of drugs for CNS disorders are
particularly difficult and characterized by several challenges:
(1) in the majority of the cases, the etiology of the disease is
unknown, (2) mimicking CNS disorders in animal models
offers a limited predictive value, (3) direct analysis of
human brain samples can in most cases only be performed
post mortem, (4) most CNS pathologies have a slow pro-
gression and can be diagnosed only when the disease is
already at an advanced stage of development, making dif-
ficult both the identification of pathogenic events and the
possible therapeutic intervention, (5) the absence or low
availability of validated biomarkers to study disease pro-
gression, and (6) the presence of the blood–brain barrier,
which limits access of compounds to the CNS, and requires
complex additional assays to measure the concentration of
drug that can effectively reach the target [117].
In this review, we have summarized the present knowl-
edge showing that NOX enzymes represent new therapeutic
targets with high potential for treatment of a large panel of
CNS disorders. However, today, most of our knowledge is
based on the protective effect of congenital absence of
NOX2 (stable knock-out mice) or pretreatment with the
antioxidant/NOX inhibitor apocynin. Therefore, alterations
or adaptive responses due to the lack of NOX2 activity
during the development of the brain cannot be excluded. As
for future directions, use of conditional knock-outs as well
as patient studies should be performed to measure NOX
expression and activation. It is still unclear, for example,
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whether increased activity of NOX2 in neurons or microglia
is responsible for diseases such as schizophrenia (with low
or no inflammation) or ALS (with a strong neuroinflam-
mation). In addition, the role of other NOX isoforms
especially NOX1 (Parkinson) and NOX4 (stroke) is only just
emerging. Nevertheless, it is striking how consistently a key
role of NOX activity is found in CNS pathologies and may
in the future represent either a therapeutic target or a bio-
marker of CNS disease progression. However, many more
studies are required to understand the exact impact of NOX
enzymes in the different human CNS pathologies.
What would be the advantages of developing
compounds to target NOX2?
If antioxidant treatments have shown no efficacy in clinical
trials, why should it be worthwhile developing compounds
to target NOX enzymes in the CNS? There are several
reasons to sustain such an effort:
1. Inhibition of ROS production at the source: antioxi-
dants act as scavengers and they are not able to prevent
the actual generation of ROS. In contrast, a molecule
designed to target NOX enzymes will be able to block
directly the source, with the possibility of having a
curative effect. Indeed, blocking NOX2-dependent
ROS production, for example in microglia, would also
allow for diminishing its activation and subsequent
production of neuroinflammatory mediators [17].
2. Specificity: antioxidant molecules do not have a
specific target and, as a consequence, their molecular
structure cannot be systematically improved. In con-
trast, developing NOX targeting molecules allow for
studying the effects of structural modifications on
potency and isoform selectivity. Structure–activity
relationships can be developed and molecules can be
improved to target the desired protein.
3. Modulation: decreasing ROS is not always the thera-
peutic solution. It has been demonstrated that in certain
pathological situations diminishing ROS can even be
deleterious, such as in autoimmune CNS diseases [63].
In those cases, targeting the NOX enzyme can allow
the design of compounds able to increase or restore
NOX activity.
How to measure NOX activity in vivo? Use
of oxidation biomarkers
Although NOX genetic deletion shows efficacy in pre-
clinical models, a key requirement for a successful
development of NOX targeted approach in humans would
be the in vivo demonstration that the targeted NOX iso-
forms are blocked. This can only be achieved by the
identification of specific biomarkers as molecular signa-
tures of excessive NOX activity. Such biomarkers would
provide extremely useful information for in vivo demon-
stration and for the organization of clinical trials. Increased
concentration of oxidized molecules in biological fluids as
biomarkers of neuropathologies is extensively documented.
As an example, increased markers of lipid peroxidation
(isoprostanes) and nucleic acid oxidation (8-oxodeoxygu-
anosine) were detected in ALS sporadic patients [106] and
PD patients [139]. However, the reliability of the correla-
tion between the presence of oxidized molecules and
disease has been questioned because of numerous unre-
solved experimental and technical flaws (for a detailed
discussion of these specific issues, see the excellent critical
review in [47]). The causes involved are the fact that
biomarkers of oxidative stress are often chemically unsta-
ble molecules, which require complicated and expensive
detection methods for reliable quantification, such as mass
spectrometry and radioimmunoassay, but also that the
source of these oxidized molecules remains unresolved.
However, levels of isoprostane, a marker of lipid per-
oxidation, and 8-hydroxy-2’-deoxyguanosine, a marker of
nucleic acid oxidation, were markedly decreased in urine
of patients with hereditary deficiency in NOX2 (CGD
patients) [155, 156]. NOX2 in CNS pathologies show a
positive relationship of isoprostanes with AD [126] and
oxidized nucleic acids in psychosis [136, 143] as well as
other CNS pathologies [112]. Such biomarkers could prove
invaluable for CNS pathologies, such as Alzheimer dis-
ease: currently the only way to tell whether a patient is
affected by AD in a conclusive manner is post mortem
histological analysis of amyloid plaques deposition.
Whether NOX enzymes are a main cause of the formation
of oxidized biomarkers in CNS disease awaits further
confirmation. This could be done by correlating the pres-
ence of isoprostanes and oxidized nucleic acids during the
progression of different neuropathological animal models
using available NOX knock-outs (i.e. NOX1, NOX2, and
NOX4). Validated oxidized biomarkers for NOX activity
would be extremely useful in drug development, such as to
assess the effect of a NOX inhibitor on disease progression,
help select drug candidates, define dose effects, and facil-
itate the selection of populations for clinical trials, and
therefore optimize chances of the successful development
of a drug, and drastically decrease development costs. It
would also help in comparing therapies (NOX inhibitors
versus antioxidant or drugs with another mode of action).
For which pathologies would it be useful to develop
NOX targeting drugs?
As mentioned above, the involvement of the NOX2
enzyme has emerged from experimental animal models of
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several incurable CNS diseases (Fig. 1). Because of the
absence of treatment, severity, and strong rational for NOX
involvement, ALS could be a primary clinical indication
for NOX inhibitors. Although ALS is quite rare, it is still
possible to recruit a sufficient number of patients to orga-
nize placebo versus treatment clinical trials, while for
recurrent Guillain Barre´, for example, its incidence is so
low that only a few patients can be included, generating
data of poor statistical significance. In the case of thera-
peutic benefit, this would pave the way to other intractable
CNS pathologies, such as Huntington disease or other more
frequent neurodegenerative diseases, including AD and
PD. A large effort is being put into the identification of
novel therapeutic options for AD with promising targets
[24]. The therapeutic benefit of NOX inhibition requires
more proof of concept animal models. Similarly to AD, the
potential for NOX inhibitors for PD and stroke as well as
activators for MS are high, but therapeutic options are
available and new drugs are emerging, so more studies will
be necessary to demonstrate an added benefit compared to
existing drugs. However, the future of drug development
for neurodegenerative disease probably relies on complex
therapies with several drugs that target various pharma-
ceutical targets, such as other anti-inflammatory drugs,
glutamate excitotoxicity, and drugs targeting neurotrans-
mitters [92, 107].
Since the discovery of chlorpromazine in 1952, little
progress has been made for the therapy of schizophrenia.
Indeed, available drugs to treat schizophrenia are not
curative and cause considerable side effects. They all target
the same pathway (dopaminergic neurotransmission), and
they primarily decrease positive symptoms, thereby
inhibiting behaviors not well tolerated by the society
(Fig. 2a). Excessive dopaminergic release may not be the
primary event, but rather the result of alteration of GAB-
Aergic-glutamatergic neurotransmission [38]. However,
these findings have not provided new opportunities for
treatment. Generation of ROS by NOX2 is emerging as a
possible novel mechanism, which (1) can first elicit the
abnormal release of glutamate and dopamine and (2) pro-
mote neurochemical adaptive responses [11, 12, 136, 143].
NOX2 would represent an upstream target to this cascade
of events, leading to the manifestation of behavioral
alterations (Fig. 2b). If the complete protection seen with
NOX2 inhibition in animal models translates into schizo-
phrenic patients, the potential for the design of novel
treatment for schizophrenia is huge and would provide a
new paradigm in the fields of psychiatric diseases.
Possible side effects of NOX therapeutics
As most CNS diseases are generally chronic diseases,
intake of NOX-based therapeutics would possibly last for
years. Therefore, side effects represent a serious concern.
Although off-targets effects are difficult to predict and can
be determined by systemic assessment of toxicity, possible
on-target side effects may result in clinical manifestations
similar to what is known from animals and humans
carrying genetic mutations in NOX genes [63, 67, 115].
Safety concerns regarding NOX inhibition include (1)
NOX2 inhibition on microglial killing and development of
hyperinflammatory states, (2) inhibition of NOX3 could
lead to balance disorders as mice affected by mutations in
NOX3 genes and its regulatory subunits show impaired
otoconia formation and balance disorders, and (3) muta-
tions affecting DUOX2 function lead to impaired thyroid
hormone synthesis and congenital hypothyroidism. The
effect of enhancing NOX2 activity, although potentially
beneficial in autoimmune diseases, might result in phago-
cyte-mediated tissue damage. Therefore, to ensure proper
monitoring of those effects, preclinical toxicity studies
should include evaluation of balance disorders, measure-
ments of circulating thyroid hormones, and inflammatory
autoimmune manifestations.
Perspectives
Today, most treatments for CNS diseases are palliative or
symptomatic, rather than curative or disease-modifying,
and hence provide only slight relief instead of a cure. Also,
they are generally associated with numerous side effects.
With the increasing understanding of the biological basis of
CNS diseases, common pathological mediators have been
Fig. 2 Schematic representation of possible use of NOX2 inhibitors
in schizophrenia. a Available antipsychotic compounds inhibit
excessive dopaminergic transmission, but not curative and are
associated with considerable side effects. b From experimental data,
it emerges that NOX2 activation could be the primary source of
neurotransmission alterations, which lead to psychotic symptoms.
Therefore, blocking NOX2 activation could represent a novel
therapeutic approach
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identified [65]. These include glutamate, ROS, aggregated
misfolded proteins, and inflammation, and, now, NOX
enzymes are emerging as key upstream regulators of at
least some of the above-mentioned features. NOX enzymes
represent promising CNS therapeutic targets as (1) they are
major ROS generators in the CNS, (2) they regulate
microglia and/or astrocyte activation, and (3) they are key
modulators of T lymphocyte activation in autoimmune
diseases.
These remarkable features show that, although NOX
enzymes are not likely to be responsible for the etiology of
CNS diseases, they represent a novel and extremely
promising therapeutic area for CNS pathologies.
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